期刊文献+

加替沙星软胶囊溶出度的测定方法研究 被引量:1

Research on determination of dissolution of gatifioxacin in Gatifioxacin Capsules
下载PDF
导出
摘要 目的:建立加替沙星软胶囊溶出度的测定方法。方法:依照《中国药典》2005年版二部附录溶出度测定项下第二法,以2%SDS的HCl(9→1000)溶液900 ml为溶出介质,转速为100 r/min,采用HPLC法测定。结果:线性关系在2.0~48.0μg/ml范围内,加替沙星浓度与峰面积的线性关系良好(r=0.9999),高中低3种浓度的平均加样回收率分别为102.4%、99.4%及98.7%,RSD为0.97%~2.9%;3批加替沙星软胶囊的溶出度为75.0%~88.0%,且溶出均一性良好。结论:本法操作简便、准确、可靠,适用于加替沙星软胶囊的质量研究。 Objective:To establish a method for determination of the dissolution of gatifioxacin in Gatifioxacin Capsules. Methods: To carry out the dissolution test (Pharmacopoeia of the People's Republic of China,Edition 2005 ,Volume 2 ,Appendix, method 2),using 900 ml HCL solution (9→1000) containing 2%SDS as the solvent,with the rotation speed adjusted to 100 r·min^-1, HPLC was adopted. Results:There was a good linearity of gatifioxacin within the range of 2.0-48.0μ g/ml (r=0.9999), the average recoveries were 102.4%, 99A%and 98.7% for three different levels of the amount of gatifioxacin,RSD were 0.97%-2.9% ;the dissolution of gatifioxaein in three batches Gatitioxacin Capsules were 75.0%-88.0%. And their dissolution homogeneity was good. Conclusion:This method is simple, quick, accurate and suitable for the quality controt of GatiEoxacin Capsules.
作者 代春江
机构地区 达县人民医院
出处 《现代医药卫生》 2009年第14期2090-2092,共3页 Journal of Modern Medicine & Health
关键词 加替沙星 溶出度 HPLC Gatifioxacin HPLC Dissolution
  • 相关文献

参考文献2

二级参考文献11

  • 1Jones RN, Croco MA, Pfaller MA, et al. Antimicrobial activity evaluation of gatifloxacin, a new fluoroquinolone:comtemporary pathogen results from a global antimicrobial resistance surveillance program(SENTRY, 1997)[J]. Clin Microbiol Infect, 1999, 5: 540-546
  • 2Jones RN, Johnson DM, Erwin ME, et al. Antistreptococcal activity of gatifloxacin[J]. Drugs, 1999, 58 (suppl.2): 164-165
  • 3Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin[J]. J Antimicrob Chemother, 1997, 40: 639-651
  • 4Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy[J]. J Antimicrob Chemother, 2001, 47: 129-140
  • 5Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection[J]. Curr Infect Dis Rep, 2001, 3: 29~34
  • 6Perry CM, Barman Balfour JA, Lamb HM. Gatifloxacin[J]. Drugs, 1999, 58:683-687
  • 7Ramirez JR, Nguyen TH, Tellier GT, et al. A prospective, randomized, double-blind, comparative study. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin[J]. J Respir Dis, 1999, 20: S40-48
  • 8Sullivan JG, McElroy AD, Honsinger RW, et al. A double-blind, randomized study of safety and efficacy. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[J]. J Respir Dis, 1999, 20: S49-59
  • 9Appelbaum PC. Quinolone activity against anaerobes[J]. Drugs, 1999, 58(suppl.2): 60-64
  • 10Lowe MN,Lamb HM. Drugs . 2000

共引文献25

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部